• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
Scientists Hunt Pandemic Hotspots in Race to Test Vaccines

Scientists Hunt Pandemic Hotspots in Race to Test Vaccines

June 1, 2020
Senate GOP Slashes Spending In ‘Big, Beautiful’ Bill As Fiscal Hawks Push For More Cuts

Senate GOP Slashes Spending In ‘Big, Beautiful’ Bill As Fiscal Hawks Push For More Cuts

June 29, 2025
NORMAN R. SEIP And DANIEL CHRISTMAN: Fair Use Or Failure: The Future Of Us-Led AI

NORMAN R. SEIP And DANIEL CHRISTMAN: Fair Use Or Failure: The Future Of Us-Led AI

June 29, 2025
Dem Senator Can’t Bring Himself To Give Trump Any Credit For Record-Low Border Numbers

Dem Senator Can’t Bring Himself To Give Trump Any Credit For Record-Low Border Numbers

June 29, 2025
Thom Tillis Announces Retirement Hours After Trump Threatened To Field Primary Challenger

Thom Tillis Announces Retirement Hours After Trump Threatened To Field Primary Challenger

June 29, 2025
STEVE MILLOY: John Thune Needs To Do Something About Obama-Era Parliamentarian Kneecapping Trump’s Megabill

STEVE MILLOY: John Thune Needs To Do Something About Obama-Era Parliamentarian Kneecapping Trump’s Megabill

June 29, 2025
Dems’ NYC Socialist Nominee Ducks And Weaves When Asked To Condemn Term Calling For Killing Jews

Dems’ NYC Socialist Nominee Ducks And Weaves When Asked To Condemn Term Calling For Killing Jews

June 29, 2025
‘A Radical Left Lunatic’: Trump Has Warning For NYC If Dems’ Socialist Nominee Pulls Any Stunts

‘A Radical Left Lunatic’: Trump Has Warning For NYC If Dems’ Socialist Nominee Pulls Any Stunts

June 29, 2025
EXCLUSIVE: Ted Cruz Fears Attempt To Scrap Provision In Trump’s Megabill Would Hand ‘Gift’ To China

EXCLUSIVE: Ted Cruz Fears Attempt To Scrap Provision In Trump’s Megabill Would Hand ‘Gift’ To China

June 29, 2025
NPR Caught Straight Up Misquoting DOGE Staffer

NPR Caught Straight Up Misquoting DOGE Staffer

June 29, 2025
Two GOP Senators Vote ‘No’ As Trump’s Megabill Clears Critical Hurdle

Two GOP Senators Vote ‘No’ As Trump’s Megabill Clears Critical Hurdle

June 28, 2025
‘Outright Massacre’: Senate GOP Takes Sledgehammer To Biden’s Green Energy Subsidies

‘Outright Massacre’: Senate GOP Takes Sledgehammer To Biden’s Green Energy Subsidies

June 28, 2025
REP. KEITH SELF: Whose Fault Is The Fiscal Mess? Time To Reform Everything

REP. KEITH SELF: Whose Fault Is The Fiscal Mess? Time To Reform Everything

June 28, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Sunday, June 29, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home News

Scientists Hunt Pandemic Hotspots in Race to Test Vaccines

by Reuters
June 1, 2020 at 7:13 am
in News
250 2
1
Scientists Hunt Pandemic Hotspots in Race to Test Vaccines

FILE PHOTO: Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds a phial containing the Ebola vaccine at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool

491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

The first wave of the COVID-19 pandemic may be waning. For vaccine developers, that could be a problem.

Scientists in Europe and the United States say the relative success of draconian lockdown and social distancing policies in some areas and countries means virus transmission rates may be at such low levels that there is not enough disease circulating to truly test potential vaccines.

They may need to look further afield, to pandemic hotspots in Africa and Latin America, to get convincing results.

“Ironically, if we’re really successful using public health measures to stamp out the hot spots of viral infection, it will be harder to test the vaccine,” said Francis Collins, director of the National Institutes of Health in the United States.

A vaccine is seen as essential to ending a pandemic that has killed nearly 370,000 people and infected more than 6 million so far, with world leaders looking at inoculation as the only real way to restart their stalled economies.

But running large-scale clinical trials of potential vaccines against a completely new disease at speed is complex, scientists say. Showing efficacy in those trials during a fluctuating pandemic adds extra difficulty – and doing so when outbreaks are waning makes it harder still.

“For this to work, people need to have a risk of infection in the community. If the virus has been temporarily cleared out, then the exercise is futile,” said Ayfer Ali, an expert in drug repurposing at Britain’s Warwick Business School.

“The solution is to move to areas where the infection is being spread widely in the community – that would be countries like Brazil and Mexico at the moment.”

Vaccine trials work by randomly dividing people into a treatment group and a control group, with the treatment group getting the experimental trial vaccine and the control group getting a placebo.

All participants go back into the community where the disease is circulating, and subsequent rates of infection are compared. The hope is that infections within the control group will be higher, showing the trial vaccine is protecting the other group.

With COVID-19 epidemics in Britain, mainland Europe and the United States coming down from their peak and transmission rates of the coronavirus dropping, a key task for scientists is to chase fluctuating outbreaks and seek volunteers in sections of populations or in countries where the disease is still rife.

A similar problem emerged when scientists were seeking to test potential new vaccines against Ebola during the vast 2014 outbreak in West Africa. Then, drugmakers were forced to drastically scale back plans for large trials because their vaccines were only test-ready late in the epidemic when case numbers were dwindling. https://reut.rs/36OmkVu

For an interactive graphic tracking the global spread, open https://tmsnrt.rs/3aIRuz7 in an external browser

LOOKING ABROAD

Among the first COVID-19 vaccines to move into phase two, or mid-stage, trials is one from the U.S. biotech company Moderna <MRNA.O> and another being developed by scientists at Oxford University supported by AstraZeneca <AZN.L>. The United States in July is planning to launch vast efficacy trials of 20,000 to 30,000 volunteers per vaccine.

Collins said U.S. health officials will tap government and industry clinical trial networks in the United States first and use mapping to detect where the virus is most active. They will also consider looking abroad if domestic disease rates fall too far, he said.

The U.S. government has experience in Africa of testing vaccines against HIV, malaria and tuberculosis.

“Africa is now beginning to experience lots of cases of COVID-19. We might very well want to run part of the trial there, where we know we can collect the data effectively,” said Collins.

Adrian Hill, director of the Jenner Institute at Britain’s Oxford University which has teamed up with AstraZeneca, started mid-stage trials last month which he said would aim to recruit around 10,000 people in Britain.

He told Reuters that with COVID-19 disease transmission rates dropping in the UK there is a possibility that the trial would have to be halted if they didn’t have enough infections to yield a result.

“That would be disappointing, and at the moment it’s unlikely, but it’s certainly a possibility,” Hill said.

CHALLENGE TRIALS

Underscoring the level of concern in the industry, AstraZeneca’s chief executive Pascal Soriot said his researchers were even contemplating running so-called “challenge” trials – where participants would be given the experimental vaccine and then deliberately infected with COVID-19 to see if it worked. Such trials are rare, high risk and hard to get ethical approval for.

As a more practical and swifter option, Soriot and others are looking to Brazil and other countries in South America, as well as parts of Africa where COVID-19 outbreaks are still growing and peaking, as ripe drug and vaccine testing grounds.

Difficulty recruiting candidates for mid-stage vaccine trials in countries where the COVID-19 pandemic is on the wane may be foreshadowed by the experience of doctors seeking infected cases for the World Health Organization’s multi-country Solidarity trial of potential treatments for the disease – including the generic drug hydroxychloroquine and Gilead’s <GILD.O> remdesivir.

In the Swiss portion of that trial, for instance, it took three weeks to get all of the ethical and regulatory approvals from authorities, and another week to get all the drugs, said Oriol Manuel, an infectious disease expert and national coordinator of the Solidarity study in Switzerland.

“We were able to enroll some patients in (one trial centre in) Lausanne,” Manuel said. “But when all centres were ready, the cases were fortunately disappearing.”

(Reporting by Kate Kelland in London, Julie Steenhuysen in Chicago and John Miller in Switzerland. Editing by Carmel Crimmins)

Tags: Coronavirus Outbreak
Share196Tweet123
Reuters

Reuters

Reuters is an international news organization.

Advertisements

Top Stories June 10th
Top Stories June 7th
Top Stories June 6th
Top Stories June 3rd
Top Stories May 30th
Top Stories May 29th
Top Stories May 24th
Top Stories May 23rd
Top Stories May 21st
Top Stories May 17th

Join Over 6M Subscribers

We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





IJR

    Copyright © 2024 IJR

Trusted Voices On All Sides

  • About Us
  • GDPR Privacy Policy
  • Terms of Service
  • Editorial Standards & Corrections Policy
  • Subscribe to IJR

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls

    Copyright © 2024 IJR

Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th